EULAR 2017

Early Treatment of 'Pre-RA' Patients May Reduce Risk of Rheumatoid Arthritis

By June 20, 2017

Study authors identified two congress abstracts and nine randomized controlled trials: eight of which were related to undifferentiated arthritis, and one which was related to very early RA.

Long-Term Baricitinib Effective, Safe for Moderate to Severe RA

By June 19, 2017

Four Phase 3 clinical trials of baricitinib in the treatment of moderate-to-severe active rheumatoid arthritis enrolled patients who were methotrexate-naïve or had inadequate response to methotrexate, conventional disease-modifying antirheumatic drugs (DMARDs) or DMARDs with TNF inhibitors.

Pegloticase Effective in Gout Patients Regardless of Clinically Apparent Tophi

By June 16, 2017

Krystexxa, a PEGylated uric acid specific enzyme, is approved for the treatment of refractory chronic gout.

Golimumab Significantly Improves Psoriatic Arthritis Symptoms

By June 16, 2017

Simponi Aria is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

Ixekizumab Effective in Psoriatic Arthritis After Inadequate TNFi Response

June 16, 2017

The SPIRIT-P2 trial will continue to evaluate long-term efficacy and safety of Taltz in PsA for up to 3 years.

CRIB Trial Evaluates Safety of Certolizumab Pegol in Pregnancy

By June 16, 2017

This first-of-its-kind study followed 16 patients at ≥30 weeks gestation who have been on Cimzia therapy for RA (n=11), CD (n=3), PsA (n=1), or axSpA/AS (n=1).

Romosozumab Cuts Fracture Risk in Postmenopausal Women with Osteoporosis

By June 16, 2017

Romosozumab, a monoclonal antibody, binds and inhibits sclerostin.

Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study

By June 16, 2017

Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.

Biosimilar BI 695501 Effective, Safe in Moderate to Severe RA

By June 15, 2017

The VOLTAIRE-RA study enrolled 645 adults aged 18-80 years with moderately-to-severely active rheumatoid arthritis on stable therapy with methotrexate.